Sample Prep & Detection Kits
Conjugation kitsPurification kitsSample preparation kitsChromogen kitsIHC kitsChIP kitsAccessory Reagents & Controls
Accessory reagents & controlsBiochemicals
BiochemicalsProteins and Peptides
Proteins and peptidesAnti-Ly6g antibody [1A8] - mouse IgG2c (Chimeric)
Low endotoxin, Azide free.
Our first-to-market chimera with mouse IgG2c backbone, this functional antibody specifically depletes neutrophils in vivo for up to 72h.
Learn about all product ranges with our product overviews.
Featured events
Make new connections at our global events.
Our programs
New Lab Program
Get a head start with our exclusive new lab discount. Enjoy 20% off and free shipping for three months.
New Biotech Program
Just starting out? Get 15% off and free shipping to your lab for six months.
Product promise
Peace of mind that all products perform as stated.
Product reviews
Leave reviews, get rewarded and help your community.
Trial program
Try untested species and applications to earn money off your next order.
Product Insider Program
Be the first to know about our latest product launches - and unlock exclusive offers and discounts.
Rabbit Recombinant Monoclonal ADAR1 antibody - conjugated to PE.
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:7972084, PubMed:7565688, PubMed:12618436). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.
Double-stranded RNA-specific adenosine deaminase, DRADA, 136 kDa double-stranded RNA-binding protein, Interferon-inducible protein 4, K88DSRBP, p136, IFI-4, ADAR1, ADAR, DSRAD, IFI4, G1P1
Rabbit Recombinant Monoclonal ADAR1 antibody - conjugated to PE.
Double-stranded RNA-specific adenosine deaminase, DRADA, 136 kDa double-stranded RNA-binding protein, Interferon-inducible protein 4, K88DSRBP, p136, IFI-4, ADAR1, ADAR, DSRAD, IFI4, G1P1
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
EPR7033
Affinity purification Protein A
The immunogen is designed to detect the p150 isoform and not the p110.
Blue Ice
1-2 weeks
+4°C
+4°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
ADAR1 plays a role in the regulation of RNA molecules affecting their stability and translation. It is linked to the editosome complex working alongside other proteins to perform RNA editing tasks. By modifying the coding potential of mRNAs ADAR1 contributes to the diversity of proteomes and helps manage the responses to viral RNAs giving the immune system tools to recognize endogenous and exogenous RNA.
ADAR1 also known as RNA-specific adenosine deaminase 1 or ADAR is an enzyme with a mass of approximately 150 kDa. This protein targets double-stranded RNA (dsRNA) and acts mechanistically to convert adenosine to inosine in pre-mRNA sequences a process known as A-to-I RNA editing. ADAR1 is expressed in numerous tissues with high levels in the brain liver and lungs. Its localization within cells can vary often found in both the nucleus and cytoplasm which influences its function.
ADAR1 is significant in the interferon signaling pathway and RNA processing pathways. It operates in coordination with proteins like PKR which is involved in the response to viral infections. ADAR1 ensures that the immune response is not directed against the self highlighting its role in the regulation of the innate immune system. These pathways are critical in maintaining homeostasis and preventing unchecked immune responses.
Mutations or dysregulation of ADAR1 have associations with autoimmune diseases like Aicardi-Goutieres syndrome and certain cancers. The enzyme's role in editing RNA makes it essential in preventing inappropriate immune attacks against the body's own cells highlighting its interaction with MDA5 another protein involved in immune regulation. Understanding ADAR1 and its related pathways may offer potential therapeutic targets for these conditions including exploration into ADAR1 inhibitors as interventions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com